

# Keshu Zhou

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/223260/publications.pdf>

Version: 2024-02-01

26  
papers

464  
citations

840776

11  
h-index

713466

21  
g-index

28  
all docs

28  
docs citations

28  
times ranked

630  
citing authors

#	ARTICLE	IF	CITATIONS
1	Treatment of Patients with Relapsed or Refractory Mantle Cell Lymphoma with Zanubrutinib, a Selective Inhibitor of Bruton's Tyrosine Kinase. <i>Clinical Cancer Research</i> , 2020, 26, 4216-4224.	7.0	126
2	Treatment of relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma with the BTK inhibitor zanubrutinib: phase 2, single-arm, multicenter study. <i>Journal of Hematology and Oncology</i> , 2020, 13, 48.	17.0	83
3	Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study. <i>Blood</i> , 2022, 139, 3148-3158.	1.4	43
4	MicroRNA-223 expression is uniformly down-regulated in B cell lymphoproliferative disorders and is associated with poor survival in patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2012, 53, 1155-1161.	1.3	32
5	miR-223 is repressed and correlates with inferior clinical features in mantle cell lymphoma through targeting SOX11. <i>Experimental Hematology</i> , 2018, 58, 27-34.e1.	0.4	24
6	Zanubrutinib monotherapy in relapsed/refractory mantle cell lymphoma: a pooled analysis of two clinical trials. <i>Journal of Hematology and Oncology</i> , 2021, 14, 167.	17.0	21
7	A Phase II Trial of the Bruton Tyrosine-Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Relapsed/Refractory Waldenström Macroglobulinemia. <i>Clinical Cancer Research</i> , 2021, 27, 5492-5501.	7.0	19
8	Intratatumoral genetic heterogeneity and number of cytogenetic aberrations provide additional prognostic significance in chronic lymphocytic leukemia. <i>Genetics in Medicine</i> , 2017, 19, 182-191.	2.4	17
9	Loss of thyroid hormone receptor interactor 13 inhibits cell proliferation and survival in human chronic lymphocytic leukemia. <i>Oncotarget</i> , 2017, 8, 25469-25481.	1.8	15
10	LINC00963 facilitates acute myeloid leukemia development by modulating miR-608/MMP-15. <i>Aging</i> , 2020, 12, 18970-18981.	3.1	15
11	The resistance mechanisms and treatment strategies of BTK inhibitors in B cell lymphoma. <i>Hematological Oncology</i> , 2021, 39, 605-615.	1.7	14
12	miR-29c down-regulation is associated with disease aggressiveness and poor survival in Chinese patients with chronic lymphocytic leukemia. <i>Leukemia and Lymphoma</i> , 2014, 55, 1544-1550.	1.3	11
13	The polymorphisms of tumor necrosis factor-induced protein 3 gene may contribute to the susceptibility of chronic primary immune thrombocytopenia in Chinese population. <i>Platelets</i> , 2016, 27, 26-31.	2.3	11
14	MiRNA-223-3p Affects Mantle Cell Lymphoma Development by Regulating the CHUK/NF- $\kappa$ B Signaling Pathway. <i>OncoTargets and Therapy</i> , 2021, Volume 14, 1553-1564.	2.0	6
15	Aberrant histone modification in CD19 <sup>+</sup> B cells of the patients with chronic lymphocytic leukemia. <i>OncoTargets and Therapy</i> , 2017, Volume 10, 1173-1179.	2.0	5
16	KIAA0101 knockdown inhibits cell proliferation and induces cell cycle arrest and cell apoptosis in chronic lymphocytic leukemia cells. <i>Annals of Translational Medicine</i> , 2021, 9, 487-487.	1.7	5
17	miRNA-223-3p modulates ibrutinib resistance through regulation of the CHUK/Nf- $\kappa$ b signaling pathway in mantle cell lymphoma. <i>Experimental Hematology</i> , 2021, 103, 52-59.e2.	0.4	5
18	Safety and Efficacy of the Bruton Tyrosine Kinase Inhibitor Zanubrutinib (BGB-3111) in Patients with Waldenström Macroglobulinemia from a Phase 2 Trial. <i>Blood</i> , 2020, 136, 42-43.	1.4	3

#	ARTICLE	IF	CITATIONS
19	Tislelizumab, a PD-1 inhibitor for relapsed/refractory mature T/NK-cell neoplasms: Results from a phase 2 study.. Journal of Clinical Oncology, 2022, 40, 7552-7552.	1.6	3
20	Efficacy and safety of G-CSF, low-dose cytarabine and aclarubicin in combination with L-asparaginase, prednisone in the treatment of refractory or relapsed acute lymphoblastic leukemia. Leukemia Research, 2017, 62, 29-33.	0.8	2
21	Preliminary Results from a Phase I Study of SHC014748M in Patients with Relapsed or Refractory Indolent B-Cell Lymphomas. Blood, 2019, 134, 4000-4000.	1.4	1
22	XPO1 Inhibitor (ATG-010) Plus Chemotherapy per Investigator's Choice for Heavily Pretreated Patients with Relapsed or Refractory (R/R) Peripheral T-Cell Lymphoma (PTCL) and Extranodal NK/T-Cell Lymphoma (ENKTL); Preliminary Results from a Multicenter, Single-Arm, Phase Ib Study (TOUCH Trial). Blood, 2021, 138, 2452-2452.	1.4	1
23	Autologous Hematopoietic Stem Cell Infusion for Myelosuppression after Bcma-CART Therapy in Relapsed Myeloma Patients. Blood, 2019, 134, 1851-1851.	1.4	0
24	The Type II Glycoengineered Humanized Anti-CD20 Monoclonal Antibody MIL62 Combined with Lenalidomide in Chinese Patients with Relapsed/Refractory Follicular Lymphoma and Marginal Zone Lymphoma: Results of a Multicenter, Single-Arm, Phase 1b/2 Trial. Blood, 2021, 138, 1351-1351.	1.4	0
25	A Phase Ib Study of Linperlisib in Patients with Relapsed or Refractory Peripheral T-Cell Lymphoma. Blood, 2021, 138, 1386-1386.	1.4	0
26	Earlier Use of Zanubrutinib Monotherapy in Patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Is Associated with Greater Efficacy: A Pooled Analysis from 3 Studies. Blood, 2020, 136, 36-37.	1.4	0